Consun Pharmaceutical Group Limited
CPHGF
$1.08
$0.0747.34%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 118.07M | 118.64M | 87.59M | 88.35M | 101.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 118.07M | 118.64M | 87.59M | 88.35M | 101.83M |
| Cost of Revenue | 28.09M | 28.22M | 22.17M | 22.36M | 26.67M |
| Gross Profit | 89.98M | 90.42M | 65.42M | 65.99M | 75.15M |
| SG&A Expenses | 51.94M | 52.19M | 37.11M | 37.43M | 46.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -741.70K | -745.30K | -475.20K | -479.40K | -3.79M |
| Total Operating Expenses | 79.28M | 79.67M | 58.80M | 59.31M | 69.56M |
| Operating Income | 38.79M | 38.98M | 28.79M | 29.04M | 32.27M |
| Income Before Tax | 40.74M | 40.94M | 29.96M | 30.22M | 33.66M |
| Income Tax Expenses | 4.85M | 4.87M | 2.28M | 2.30M | 3.28M |
| Earnings from Continuing Operations | 35.89M | 36.07M | 27.68M | 27.92M | 30.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -397.70K | -399.60K | -82.50K | -83.20K | -144.30K |
| Net Income | 35.50M | 35.67M | 27.60M | 27.84M | 30.24M |
| EBIT | 38.79M | 38.98M | 28.79M | 29.04M | 32.27M |
| EBITDA | 40.19M | 40.38M | 31.31M | 31.58M | 34.76M |
| EPS Basic | 0.04 | 0.04 | 0.03 | 0.03 | 0.04 |
| Normalized Basic EPS | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 |
| EPS Diluted | 0.04 | 0.04 | 0.03 | 0.03 | 0.04 |
| Normalized Diluted EPS | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 |
| Average Basic Shares Outstanding | 840.59M | 840.59M | 801.61M | 801.61M | 792.50M |
| Average Diluted Shares Outstanding | 853.31M | 853.31M | 810.91M | 810.91M | 801.71M |
| Dividend Per Share | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Payout Ratio | 45.10% | 45.10% | 112.62% | 112.62% | 27.07% |